Journal
BONE MARROW TRANSPLANTATION
Volume 57, Issue 2, Pages 198-206Publisher
SPRINGERNATURE
DOI: 10.1038/s41409-021-01518-0
Keywords
-
Categories
Funding
- NIH [CA018029]
- NIH/NCI [T32 CA009515]
- American Society of Hematology Research Training Award for Fellows (RTAF)
- Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair
Ask authors/readers for more resources
In this study, long-term outcomes in MDS and AML patients receiving different conditioning regimens were evaluated, with BuFluTHY conditioning associated with lower rates of chronic GVHD and long-term mixed T-cell chimerism, but potentially higher risks of relapse and non-relapse mortality.
We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related or unrelated donors following conditioning with targeted busulfan (Bu, over 4 days), fludarabine (Flu, 120 [n = 23] or 250 [n = 17] mg/m(2)) and thymoglobulin (THY). Compared to 95 patients conditioned with Bu/Cyclophosphamide (Cy) without THY, BuFluTHY-conditioned patients had lower rates of chronic graft-vs.-host disease (GVHD). Adjusted hazard ratios (HR) for BuFlu(120)THY and BuFlu(250)THY-conditioned patients were 1.60 (95% confidence interval (CI) 0.66-3.86) and 1.87 (0.68-5.11), respectively, for relapse; 0.77 (0.30-1.99) and 1.32 (0.54-3.23) for non-relapse mortality; 0.81 (0.42-1.57) and 1.38 (0.72-2.57) for overall mortality; and 0.78 (0.30-2.05) and 1.62 (0.63-4.41) for relapse or death (failure for relapse-free survival). At one year, 45% of BuFlu(120 or 250)THY-conditioned patients had mixed CD3+ chimerism compared to 0% with BuCy (p < 0.0001). None of 7 patients with long-term mixed chimerism had chronic GVHD; two relapsed, five remained stable mixed chimeras. THY is effective in reducing chronic GVHD, and long-term mixed T-cell chimerism can be compatible with relapse-free survival. However, Thy may also be associated with an increased risk of relapse and, dose-dependent, with non-relapse mortality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available